DGAM
ALNY icon

Desjardins Global Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Desjardins Global Asset Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		$88.8K Buy
464
+6
+1% +$1.02K 0.01% 483
2023
Q3 		$81.1K Buy
+458
New +$87.4K 0.01% 492

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Desjardins Global Asset Management's ALNY Position: Q4 2023 in Review

Desjardins Global Asset Management increased its Alnylam Pharmaceuticals (ALNY) stake by 1.3% in Q4 2023, buying an estimated $1.02K and bringing the position to 464 shares worth $88.8K. The position accounts for 0.01% of the portfolio, ranked #483.

Desjardins Global Asset Management first reported a position in ALNY in Q3 2023 and has held it in 2 quarters since. 498 funds tracked by Wall St. Rank hold ALNY as of Q4 2023.

  • Desjardins Global Asset Management held 464 shares of Alnylam Pharmaceuticals worth $88.8K as of Q4 2023.
  • Desjardins Global Asset Management bought 6 Alnylam Pharmaceuticals shares in Q4 2023, an estimated $1.02K.
  • Alnylam Pharmaceuticals made up 0.01% of Desjardins Global Asset Management's portfolio in Q4 2023, its #483 holding.
  • Desjardins Global Asset Management first reported a position in Alnylam Pharmaceuticals in Q3 2023 and has held it in 2 quarters since.
  • 498 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2023.

Based on Desjardins Global Asset Management's 13F filing for Q4 2023, filed 30 Jan 2024.